Shares of Lucid fall after the company says it received a subpoena from the Securities and Exchange Commission.
Ever since Nvidia (NASDAQ: NVDA) released strong earnings results for the third quarter of fiscal 2022 on Nov. 17, 2021, the stock has been going downhill, due to a variety of factors out of the company's control. Shares of the graphics card specialist are down 30% since its Q3 report as the strong probability of interest rate hikes by the Federal Reserve and the crash in cryptocurrencies has weighed on investor sentiment. After all, interest rate hikes are bad news for richly valued companies such as Nvidia as rising U.S. Treasury yields mean that investors can get more returns by shifting their money to safer assets.
Industrial giant 3M just lost a big legal case, and it helps explain why investors are so downbeat on the shares.
Yahoo Finance’s Jared Blikre breaks down the latest Apple earnings report.
Boeing might be on the cusp of an all-new airplane. Details are thin but the news should excite weary Boeing investors. Bloomberg reported that Boeing (ticker: BA) commercial airplanes chief Stan Deal told the Royal Aeronautical Society this week that his company was in the early stages of developing a new plane.
Jim Cramer has never been shy to use buzzers and bells to make the occasionally esoteric world of finance more interesting.
Investing $200,000 in this basket of dividend stocks should earn you $12,800 in passive income in 2022.
Novavax Inc. said Friday it will supply 5 million doses of its protein-based COVID-19 vaccine to Israel as part of an advance purchase agreement, with the Israeli Ministry of Health also taking an option to buy an additional 5 million doses. "Novavax will work with the Ministry of Health to obtain the necessary authorizations and finalize plans for distribution in Israel pending regulatory approval," the company said in a statement. Novavax is currently conducting two Phase 3 trials of the vacci
It's not something investors like to think about, but stock market crashes and corrections are a normal part of the investing cycle and the price long-term investors pay for admission to one of the world's greatest wealth creators. The tech-heavy Nasdaq Composite has entered correction territory, while the benchmark S&P 500 is contending with its worst slide in more than a year. While stock market corrections can be unnerving, they're also, historically, the perfect time to put money to work in the market -- especially if your average holding period is measured in years.
"Dampening" reservations means analyst predictions of a return to profits this year could be all wet.
AMD's relatively cheap valuation and its ability to keep growing at a rapid pace make the stock worth buying.
The world is abuzz about the metaverse, an evolving technology that could reshape life as we know it. It describes a network of immersive virtual worlds that blend elements of social media, gaming, entertainment, and commerce, effectively creating a brand new economy. In fact, a recent Bloomberg report called the metaverse the "next big technology platform," and it put the market opportunity at $800 billion by 2024.
Tesla is the world's largest maker of electric vehicles, but doesn't seem to be getting recognition from President Joe Biden. CEO Elon Musk continues to make noise about it on Twitter.
In what follows, we'll look at two stocks that are changing hands for well under $100 per share and that look attractive at current levels: Pfizer (NYSE: PFE) and Teladoc Health (NYSE: TDOC). Pfizer's coronavirus lineup alone will likely generate more sales than most pharmaceutical companies this year. Meanwhile, Pfizer's newly approved coronavirus medicine, Paxlovid, could generate upward of $10 billion.
Over the next two decades, artificial intelligence (AI) will contribute $30 trillion to the global equity market cap, according to Ark Invest. It makes content and product recommendations more relevant. For instance, fintech companies like Upstart Holdings (NASDAQ: UPST) and Riskified (NYSE: RSKD) are using AI to minimize risk for banks and e-commerce merchants, helping them operate more efficiently and more profitably.
Despite positive material updates, the biotech's shares couldn't escape the market-wide downturn among growth stocks this week.
It's recently been caught up in multiple negative headlines, but has the business itself been affected?
Certainly you’ve been watching the stock market over the past few days. The recent stock market volatility, following years of up markets, is nevertheless the most widely forecast financial reversal in recent history. For them I offer a fundamental insight, one which can escape even seasoned investors.
Investors who take an interest in NextEra Energy, Inc. ( NYSE:NEE ) should definitely note that the Independent...
Investors may soon be able to preserve their retirement war chest for longer. The Securing a Strong Retirement Act, a bill originally pushed in 2021 but which may finally pass this year, would push the starting point for required minimum … Continue reading → The post RMDs May Soon Start Even Later for Retirement Plan Savers appeared first on SmartAsset Blog.
Prices of tokens like Dogecoin (CRYPTO: DOGE) and Shiba Inu (CRYPTO: SHIB) soared and plunged at various points throughout 2021 as a direct result of social-media hype, but still ended the year far above where they began it. Here's why you'll want to consider buying Upstart (NASDAQ: UPST), a young fintech company that's remakting the lending business, instead of Dogecoin or Shiba Inu. Upstart is disrupting the traditional FICO-based lending model, which rates borrowers based on a handful of metrics and has been used by financial institutions since 1989.